FDA sent a warning letter , dated March 26, 2018, to Tris Pharma Inc. after investigators inspected the company s Monmouth Junction, NJ facility and found deviations in current good manufacturing practices (CGMP). During the inspection, which was conducted Feb. 14 to March 20, 2017, inspectorOriginal Article
You may also like
Nouscom to present re‑treatment data in Lynch...
ViiV Healthcare to unveil new HIV treatment data at...
Almirall’s paediatric registration of Ebglyss for...
The Bloc appoints Jon Chapman as European Executive...
UCSD, IGI Partnership Expands CRISPR Innovation Across...
10x Clinical Expansion Advances with CLIA Lab Plans...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.